The maturing immune system: implications for development and testing HIV-1 vaccines for children and adolescents
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Introduction Development of an effective HIV-1 vaccine would greatly advance prospects for control of the AIDS epidemic. To date, development of vaccine candidates has been of limited success, demanding innovative approaches to vaccine technology [1]. Inactivated and live attenuated vaccine technology, so successful in vaccinology of other pathogens, is considered too risky for HIV infection [1,2]. Subunit vaccines have been ineffective, failing to elicit neutralizing antibody responses [3,4]. Therefore sterilizing immunity, which is thought to be critical for prevention of infection, seems an unlikely prospect [5]. Current promising DNA and vector-based vaccine candidates in or about to enter phase I trials (www.iavi.org; http://chi.ucsf.edu/vaccines/) are designed to induce cellular immune responses that prevent persistent infection or disease development rather than acquisition of infection. Even if these problems are overcome, the clinical testing of a successful vaccine is estimated to take at least 10 years with the best collaborative global efforts. In 2005, the devastating impact of the HIV/AIDS pandemic continues unabated. UNAIDS estimates that 3.5 million people were newly infected with HIV in the year 2003 and that 700 000 of these infections occurred in those aged less than 15 years [6], most living in sub-Saharan Africa. Paediatric HIV infections are acquired both vertically and horizontally [7], and HIV vaccines might be developed to combat both modes of transmission. A vaccine administered in the neonatal period would almost certainly not prevent HIV infections due to in utero or intrapartum exposure. However, breast-feeding by infected mothers carries a risk of vertical transmission especially in developing countries where formula milk feeding is either unavailable or unaffordable and may itself be associated with a high risk of morbidity. A vaccine that induced an effective immune response in the newborn could reduce this transmission. Horizontal transmission is predominantly sexual, and in sub-Saharan African countries sexual debut can be as young as 10 years, with much trans-generational sex, putting the pre-adolescent at risk for HIV acquisition [8–12]. Adolescents in the developed world are also at high risk of acquiring HIV-1, with 20 000 new infections in 13–24-year olds annually in the United States alone [13]. Children and adolescents are therefore important targets for a preventative HIV vaccine. HIV vaccine clinical trials to date have been conducted almost exclusively in adults. None of the preventative HIV vaccine trials have included adolescents and only two completed trials targeted HIV-1 exposed neonates (PACTG 326 and PACTG 230) [14–19]. In order to license a vaccine for use in children, data should exist on the safety and immunogenicity or efficacy of the vaccine in this age group. Development of vaccines in children is facilitated where there are specific correlates of immunity. For example, trials in adults demonstrated that hepatitis B surface antibody (HepBsAb) titres of greater than 10 IU/l conferred protection against hepatitis B infection. The use of this surrogate marker enabled testing and approval of the recombinant Hepatitis B vaccine for neonates [20,21]. However, in the absence of correlates of immunity to HIV-1 infection the approval of a vaccine for children will require efficacy data and will thus take longer. Inclusion of children and adolescents in clinical trial research and particularly HIV vaccine trials is difficult [22]. Ethico-legal issues concerning age of informed consent, protection of children, and reporting of illegal sexual activity and sexually transmitted diseases confront researchers. Socio-behavioral issues include assessment of true understanding of the consent form and possible disinhibition of sexual behaviour whilst participating in trials. There is also a lack of experience in recruiting and retaining adolescents and the provision of youth-friendly services. These are thought to be an important prerequisite for adolescent trials, and are non-existent in many HIV trial sites [23]. Yet these problems can and must be addressed. There are physiological and immunological differences between children and adults that may change the safety and efficacy of developed vaccines. The purpose of this review is primarily to highlight the immunological differences between infants, adolescents and adults and to describe some of the reported disparities between these age groups in their responses to licensed as well as other experimental vaccines. Age-dependent immune function Generally, the immune response has two separate although highly integrated and interdependent components, namely the innate and adaptive responses. While novel approaches are being considered to enhance innate responses to vaccination, the adaptive immune system is of principal importance in vaccinology due to its specificity and memory. Neutralizing antibodies block viral entry i
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dunkle, K. L., Jewkes, R. K., Brown, H. C., Gray, G. E., McIntryre, J. A., & Harlow, S. D. (2004) · Social Science & Medicine · doi:10.1016/j.socscimed.2004.02.003 · Cited by 566
Development of interleukin-12-producing capacity throughout childhood
Upham, J. W., Lee, P. T., Holt, B. J., Heaton, T., Prescott, S. L., Sharp, M. J., Sly, P. D., & Holt, P. G. (2002) · Infection and Immunity · doi:10.1128/iai.70.12.6583-6588.2002 · Cited by 257 · cited 1×
“Thus, for example, oestrogen treatment of BALB/c mice increases the frequency of IL-6 and IL-10-secreting cells, promoting B cell activation, plasma cell maturation and IgG production [106] Neonatal CD4 cells are less able to provide help for Ig synthesis [37,38] DHEA and DHEA sulfate inhibit TH2 responses and promote…”
Background
Cited by
Neonatal Cytokine Profiles Associated With Autism Spectrum Disorder
Krakowiak, P., Goines, P. E., Tancredi, D. J., Ashwood, P., Hansen, R. L., Hertz-Picciotto, I., & Van de Water, J. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.08.007 · Cited by 249
“The neonatal immune system is extremely immature, and cytokine production is much lower than in adults (32); this was accurately reflected by the number of subjects whose wholeblood cytokine levels were near or below the limit of detection.”
BackgroundStearns, J. C., Davidson, C. J., McKeon, S., Whelan, F. J., Fontes, M. E., Schryvers, A. B., Bowdish, D. M. E., Kellner, J. D., & Surette, M. G. (2015) · The ISME Journal · doi:10.1038/ismej.2014.250 · Cited by 234
Pensieroso, S., Cagigi, A., Palma, P., Nilsson, A., Capponi, C., Freda, E., Bernardi, S., Thorstensson, R., Chiodi, F., & Rossi, P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901702106 · Cited by 165
Adolescent Participation in HIV Vaccine Trials: Cognitive Developmental Considerations
Kafaar, Z., Swartz, L., Kagee, A., Lesch, A., & Jaspan, H. (2007) · South African Journal of Psychology · doi:10.1177/008124630703700312 · Cited by 9
Self-citation
Metadata
- Authors
- Jaspan, H. B., Lawn, S. D., Safrit, J. T., & Bekker, L.-G.
- Venue
- AIDS
- Published
- 2006-02-28
- Volume
- 20
- Issue
- 4
- Pages
- 483-494
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2043330521
- Cited by
- 81
- References
- 2
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The maturing immune system: implications for development and testing HIV-1 vaccines for children and adolescents. https://app.cochat.ai/papers/10.1097/01.aids.0000210602.40267.60
- The paper
- Jaspan, H. B., Lawn, S. D., Safrit, J. T., & Bekker, L.-G. (2006). The maturing immune system: implications for development and testing HIV-1 vaccines for children and adolescents. AIDS. https://doi.org/10.1097/01.aids.0000210602.40267.60
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.